None listed
Conditions
Interventions
Intervention1: 1. Acne buster lotion 10%: Acne buster is a mixture of cosmetic ingredients and each ingredient has safety certificate of ingredient.
Intervention2: Acne buster 3%: (lower concentration
1-3 Butylene Glycol 50%, water 49.1%, plant extract 0.9%. Since the majority of the extract is Butylene glycol and water. So, we assume that there will not be any adverse effects on skin.
Interventio
Sponsors
ICHIMARU PHARCOS CO Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1)Subjects with skin type III to V. 2)Subjects willing to give a written informed consent. 3)Subjects willing to maintain the patch test in position for 24 hours 4)Subject has not participated in a similar investigation in the past two weeks. 5)Subjects willing to come for regular follow up. 6)Subjects ready to follow instructions during the study period.
Exclusion criteria
Exclusion criteria: 1)Infection, allergy on the tested area 2)History of skin allergy antecedents or atopic subjects 3)History of hyper sensitivity to any component of the tested products 4)Athletes and subjects with history of excessive sweating 5)Cutaneous disease which may influence the study result 6)Chronic illness which may influence the cutaneous state. 7)Subjects on oral corticosteroid with dose >10mg/day 8)Subjects participating in any other cosmetic or therapeutic trial. 9)Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test.Timepoint: To evaluate the dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test on Day 1, Day 2 & Day 7 of post patch application. | — |
Secondary
| Measure | Time frame |
|---|---|
| To gather safety information prior to a pilot study and/or larger study, in order to improve the latterâ??s quality and efficiency of the study design.Timepoint: Dermatological safety of the given investigational product/s on skin of healthy human volunteers by primary irritation patch test on Day 1, Day 2 & Day 7 of post patch application. | — |
Countries
India
Contacts
Public ContactDr Mukta Sachdev
MS CLINICAL RESEARCH PVT. LTD
Outcome results
None listed